Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Figures corrected afterwards (2023).
Gross margin
€ -377,020
▼ 17% vs 2024
Profit
Caution€ -2.2 million
▼ 100% vs 2024
Debts
Low€ 1.4 million
▲ 235% vs 2024
Temmune Therapeutics from Mechelen, company number BE0776938722, closed financial year 2025 with a result of € -2.2 million after tax. For that financial year Temmune Therapeutics recorded a gross margin of € -377,020 and equity of € 2 million. Compared with financial year 2024, the result moved from € -1.1 million to € -2.2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 7, 2026.
What happened at Temmune Therapeutics?
What happened at Temmune Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Participatiemaatschappij Vlaanderen NV stepped down as director. NBB
- Tomas Heyman stepped down as director. NBB
- Roderick Verhelst stepped down as director. NBB
- Keith McCullagh stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.2 million. Source: NBB ↗
- Participatiemaatschappij Vlaanderen NV became a director. NBB
- Tomas Heyman became a director. NBB
- Dirk Reyn stepped down as director. NBB
In short
From € 744,736 loss in 2022 to € 2.2 million loss in 2025.
A new publication or filing at Temmune Therapeutics? We notify you, reason included.
Follow Temmune TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Temmune Therapeutics is LIFE of SCI BV. LIFE of SCI BV is also behind Invigo Therapeutics.
Directors
According to the 2025 annual accounts
Persoon belast met dagelijks bestuur · represented by De Maeyer Joris
Also active at: Invigo Therapeutics
since 2025
Participatiemaatschappij Vlaanderen NV
Director · represented by Wilms Tobias
Also active at: VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK, Arts Gebroeders immobilière, BEDRIJVENCENTRUM VILVOORDE +141 more
since 2025 · until 2031
Tomas Heyman
Director
since 2025 · until 2031
since 2024 · until 2025
Roderick Verhelst
Director
since 2024 · until 2030
Keith McCullagh
Director
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Kardinaal Mercierplein 2
2800 Mechelen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 37 companies are registered at this address.
FRUTAROM BELGIUM
€ 2.2 million revenue · 2025
Motorola Solutions Belgium
€ 931,294 gross margin · 2025
ESKENS BENELUX
€ 276,312 gross margin · 2025
HERA
€ 477,015 gross margin · 2025
ICON Clinical Research Belgium
€ 42.5 million revenue · 2024
+32 more
Details
- Company number
- 0776.938.722
- VAT number
- BE 0776.938.722
- Registered office
- Kardinaal Mercierplein 2, 2800 Mechelen
- Names & denominations
- Temmune Therapeutics · TemmuneTx
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 8 November 2021
- Peppol
- Active · Active since 6 May 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Vervaardiging van overige farmaceutische producten
Overige gespecialiseerde wetenschappelijke en technische activiteiten